Brain metabolic correlates of Locus Coeruleus degeneration in Alzheimer's disease: a multimodal neuroimaging study
- PMID: 36463849
- DOI: 10.1016/j.neurobiolaging.2022.11.002
Brain metabolic correlates of Locus Coeruleus degeneration in Alzheimer's disease: a multimodal neuroimaging study
Abstract
Locus Coeruleus (LC) degeneration occurs early in Alzheimer's disease (AD) and this could affect several brain regions innervated by LC noradrenergic axon terminals, as these bear neuroprotective effects and modulate neurovascular coupling/neuronal activity. We used LC-sensitive Magnetic Resonance imaging (MRI) sequences enabling LC integrity quantification, and [18F]Fluorodeoxyglucose (FDG) PET, to investigate the association of LC-MRI changes with brain glucose metabolism in cognitively impaired patients (30 amnesticMCI and 13 demented ones). Fifteen cognitively intact age-matched controls (HCs) were submitted only to LC-MRI for comparison with patients. Voxel-wise regression analyses of [18F]FDG images were conducted using the LC-MRI parameters signal intensity (LCCR) and LC-belonging voxels (LCVOX). Both LCCR and LCVOX were significantly lower in patients compared to HCs, and were directly associated with [18F]FDG uptake in fronto-parietal cortical areas, mainly involving the left hemisphere (p < 0.001, kE > 100). These results suggest a possible association between LC degeneration and cortical hypometabolism in degenerative cognitive impairment with a prevalent left-hemispheric vulnerability, and that LC degeneration might be linked to large-scale functional network alteration in AD pathology.
Keywords: Alzheimer's disease; Locus Coeruleus; Locus Coeruleus Integrity; Magnetic Resonance imaging; [18F]Fluorodeoxyglucose Positron Emission Tomography.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Authors Gayane Aghakhanyan, Alessandro Galgani, Francesco Lombardo, Nicola Martini, Filippo Baldacci, Gloria Tognoni, Andrea Leo, Federica Guidoccio, Gabriele Siciliano, Francesco Fornai, Duccio Volterrani, Filippo S. Giorgi declare they have no financial conflicts of interests and nothing to disclose. AV declares no competing financial interests related to the present article, and his contribution to this article reflects only and exclusively his own academic expertise on the matter. This work is linked to his previous academic position at Sorbonne University, Paris, France. AV was an employee of Eisai Inc. [Nov 2019 - June 2021]. AV has not received any fees or honoraria since November 2019. Before November 2019 he had he received lecture honoraria from Roche, MagQu LLC, and Servier. Nicola Pavese has received Advisory Boards honoraria from: Britannia, Bial, Boston Scientific, Benevolent AI, Roche, Abbvie. 4D Pharma; Speaker Honoraria from: Britannia, Abbvie, GE Healthcare, Boston Scientific, the MDS. He has received research grants from the Independent Research Fund Denmark, Danish Parkinson's disease Association, Parkinson's UK, Center of Excellence in Neurodegeneration (CoEN) network award, GE Healthcare Grant, Multiple System Atrophy Trust, Weston Brain Institute, EU Joint Program Neurodegenerative Disease Research (JPND), the MJFF, and the EU Horizon 2020 research and innovation programme.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical